Compare GIII & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | ANAB |
|---|---|---|
| Founded | 1956 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2006 | 2015 |
| Metric | GIII | ANAB |
|---|---|---|
| Price | $34.11 | $66.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $29.00 | ★ $71.67 |
| AVG Volume (30 Days) | 606.9K | ★ 646.4K |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $2,957,012,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | $22.90 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $22.92 | $17.11 |
| 52 Week High | $36.53 | $73.30 |
| Indicator | GIII | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 59.18 |
| Support Level | $31.83 | $52.32 |
| Resistance Level | $34.83 | $70.06 |
| Average True Range (ATR) | 1.01 | 4.15 |
| MACD | -0.05 | 0.56 |
| Stochastic Oscillator | 63.39 | 70.97 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).